Track topics on Twitter Track topics that are important to you
Looking ahead, Smith says: ''The priorities for us without doubt are third party deals on both sides - be they licensing deals, supply deals etc on the reagents and diagnostics side and we've got a really full pipeline of high quality partners evaluating the technology''.
''We have sufficient going on in the pipeline to be confident those deals will start to come through this year and into 2019 and onwards''.
''On the therapeutics side we've got a lot of confidence now we can do deals at a preclinical stage''.
Smith also discusses the appointment of Dr Eliot Forster as non-executive chairman to the board.NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...